Provention Bio Operating Income

Provention Bio (PRVB) currently reports a operating income of $-130M as of December 2022. That compares with $-120M in the prior-year period — down 10.9% year over year. Use the charts on this page to explore Provention Bio's operating income history and peer comparisons.

Provention Bio's operating income decreased from $-120M to $-130M — a 10.9% year-over-year decrease (period ending December 2022). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Provention Bio reported $-130M in operating income as of December 2022. That compares with $-120M in the prior-year period — down 10.9% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current operating income of $-130M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Provention Bio, and consider following PRVB for alerts when major investors trade the stock.

Provention Bio is classified in the Healthcare sector. On operating income, it currently shows $-130M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing PRVB with unrelated industries.